Mga Batayang Estadistika
| CIK | 1413119 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kraig Biocraft Laboratories, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
424B3 Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 2 Dated August 18, 2025 (To Prospectus Dated May 5, 2025) 424B3 Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wy |
|
| August 18, 2025 |
424B3 Kraig Biocraft Laboratories, Inc. 207,787,193 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-284773 Prospectus Supplement No. 2 Dated August 18, 2025 (To Prospectus Dated May 6, 2025) 424B3 Kraig Biocraft Laboratories, Inc. 207,787,193 Shares of Class A Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyoming corporation (the “Comp |
|
| August 18, 2025 |
424B3 Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 2 Dated August 18, 2025 (To Prospectus Dated May 5, 2025) 424B3 Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wy |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAIG BIO |
|
| May 20, 2025 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 1 Dated May 20, 2025 (To Prospectus Dated May 5, 2025) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyoming cor |
|
| May 20, 2025 |
Kraig Biocraft Laboratories, Inc. 207,787,193 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-284773 Prospectus Supplement No. 1 Dated May 20, 2025 (To Prospectus Dated May 6, 2025) Kraig Biocraft Laboratories, Inc. 207,787,193 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyoming corporation (the “Company,” “we |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAIG BI |
|
| May 6, 2025 |
KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Pursuant to this prospectus, the selling shareholders identified herein (each a “Selling Shareholder” and, collectively, the “Selling Shareholders”) are offering on a resale basis, up to 306,124,163 shares of common stock, |
|
| May 6, 2025 |
KRAIG BIOCRAFT LABORATORIES, INC. Up to 207,787,193 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-284773 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. Up to 207,787,193 Shares of Common Stock This prospectus relates to the resale from time to time of up to 207,787,193 shares of common stock, par value $0.0001 per share (“Common Stock”), of Kraig Biocraft Laboratories, Inc., a Wyoming corporation (“Kraig Biocraft Laboratories” or the “Company |
|
| April 29, 2025 |
As submitted to the Securities and Exchange Commission on April 28, 2025 As submitted to the Securities and Exchange Commission on April 28, 2025 Registration No. |
|
| April 29, 2025 |
As submitted to the Securities and Exchange Commission on April 28, 2025 As submitted to the Securities and Exchange Commission on April 28, 2025 Registration No. |
|
| April 17, 2025 |
As submitted to the Securities and Exchange Commission on April 17, 2025 As submitted to the Securities and Exchange Commission on April 17, 2025 Registration No. |
|
| April 17, 2025 |
As submitted to the Securities and Exchange Commission on April 17, 2025 As submitted to the Securities and Exchange Commission on April 17, 2025 Registration No. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-56232 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issuer |
|
| February 14, 2025 |
As submitted to the Securities and Exchange Commission on February 14, 2025 As submitted to the Securities and Exchange Commission on February 14, 2025 Registration No. |
|
| February 14, 2025 |
Kraig Biocraft Laboratories, Inc. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 Kraig Biocraft Laboratories, Inc. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 February 14, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.C., 20549 Re: Kraig Biocraft Laboratories, Inc. Registration Statement on Form S-1 (File No. 333-284773) Request for Acceleration o |
|
| February 13, 2025 |
As submitted to the Securities and Exchange Commission on February 13, 2025 As submitted to the Securities and Exchange Commission on February 13, 2025 Registration No. |
|
| February 7, 2025 |
As submitted to the Securities and Exchange Commission on February 7, 2025 As submitted to the Securities and Exchange Commission on February 7, 2025 Registration No. |
|
| February 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Kraig Biocraft Laboratories, Inc. |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) |
|
| January 21, 2025 |
Exhibit 99.1 Kraig Biocraft Laboratories Secures $10 Million SEPA to Support Spider Silk Production Growth and Commercialization ANN ARBOR, Mich., – January 21, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, announces that it has secured $10 million in a standby equity purchase agreement (“SEPA”) with YA II PN |
|
| January 21, 2025 |
Exhibit 10.1 |
|
| December 19, 2024 |
Kraig Biocraft Laboratories, Inc. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 Kraig Biocraft Laboratories, Inc. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 December 19, 2024 Via EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Re: Kraig Biocraft Laboratories, Inc. Withdrawal of Pre-Effective Amendment No. 16 to Registration Statement on Form S-1 (File No. 333-238883) D |
|
| December 9, 2024 |
As submitted to the Securities and Exchange Commission on December 9, 2024 As submitted to the Securities and Exchange Commission on December 9, 2024 Registration No. |
|
| November 19, 2024 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 2 Dated November 19, 2024 (To Prospectus Dated June 5, 2024) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyomi |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAI |
|
| August 16, 2024 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 1 Dated August 16, 2024 (To Prospectus Dated June 5, 2024) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyoming |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAIG BIO |
|
| June 10, 2024 |
KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Pursuant to this prospectus, the selling shareholders identified herein (each a “Selling Shareholder” and, collectively, the “Selling Shareholders”) are offering on a resale basis, up to 306,124,163 shares of common stock, |
|
| May 29, 2024 |
As submitted to the Securities and Exchange Commission on May 29, 2024 As submitted to the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAIG BI |
|
| April 1, 2024 |
Exhibit 4.2 Description of Securities General Our original articles of incorporation authorized 60,000,000 shares of Class A common stock, 25,000,000 shares of Class B common stock with no par value per share and 10,000,000 shares of preferred stock with no par value per share. On March 18, 2009, we amended our articles of incorporation to provide for unlimited authorized shares, no par value, of |
|
| April 1, 2024 |
Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Name State of Incorporation Prodigy Textiles Ltd (Vietnam) |
|
| April 1, 2024 |
Exhibit 19.1 Insider Trading Policy The following is the insider trading policy of Kraig Biocraft Laboratories, Inc. (the “Company”) and outlines the procedures that all Company personnel must follow to comply with company policy. This policy arises from our responsibilities as a public company. Failure to comply with these procedures could result in termination of employment. If the breach of com |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-56232 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issuer |
|
| April 1, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) (Co |
|
| November 22, 2023 |
As submitted to the Securities and Exchange Commission on November 22, 2023 As submitted to the Securities and Exchange Commission on November 22, 2023 Registration No. |
|
| November 16, 2023 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 1 Dated November 16, 2023 (To Prospectus Dated September 1, 2023) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAI |
|
| September 11, 2023 |
KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Pursuant to this prospectus, the selling shareholders identified herein (each a “Selling Shareholder” and, collectively, the “Selling Shareholders”) are offering on a resale basis, up to 306,124,163 shares of common stock, |
|
| September 1, 2023 |
As submitted to the Securities and Exchange Commission on September 1, 2023 As submitted to the Securities and Exchange Commission on September 1, 2023 Registration No. |
|
| September 1, 2023 |
As submitted to the Securities and Exchange Commission on September 1, 2023 As submitted to the Securities and Exchange Commission on September 1, 2023 Registration No. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAIG BIO |
|
| June 6, 2023 |
As submitted to the Securities and Exchange Commission on June 6, 2023 As submitted to the Securities and Exchange Commission on June 6, 2023 Registration No. |
|
| May 18, 2023 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 1 Dated May 18, 2023 (To Prospectus Dated April 14, 2023) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyoming |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAIG BI |
|
| May 9, 2023 |
As submitted to the Securities and Exchange Commission on May 9, 2023 As submitted to the Securities and Exchange Commission on May 9, 2023 Registration No. |
|
| April 27, 2023 |
As submitted to the Securities and Exchange Commission on April 27, 2023 As submitted to the Securities and Exchange Commission on April 27, 2023 Registration No. |
|
| April 14, 2023 |
As submitted to the Securities and Exchange Commission on April 14, 2023 As submitted to the Securities and Exchange Commission on April 14, 2023 Registration No. |
|
| April 14, 2023 |
As submitted to the Securities and Exchange Commission on April 14, 2023 As submitted to the Securities and Exchange Commission on April 14, 2023 Registration No. |
|
| March 29, 2023 |
Exhibit 4.2 Description of Securities General Our original articles of incorporation authorized 60,000,000 shares of Class A common stock, 25,000,000 shares of Class B common stock with no par value per share and 10,000,000 shares of preferred stock with no par value per share. On March 18, 2009, we amended our articles of incorporation to provide for unlimited authorized shares, no par value, of |
|
| March 29, 2023 |
Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Name State of Incorporation Prodigy Textiles Ltd (Vietnam) |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 000-56232 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issuer |
|
| December 1, 2022 |
As submitted to the Securities and Exchange Commission on December 1, 2022 As submitted to the Securities and Exchange Commission on December 1, 2022 Registration No. |
|
| November 17, 2022 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 3 Dated November 17, 2022 (To Prospectus Dated April 19, 2022) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 3 (the ?Prospectus Supplement?) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyo |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-56232 KRAI |
|
| August 12, 2022 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 2 Dated August 12, 2022 (To Prospectus Dated April 19, 2022) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 2 (the ?Prospectus Supplement?) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyomi |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRAIG BI |
|
| May 25, 2022 |
As submitted to the Securities and Exchange Commission on May 25, 2022 As submitted to the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 10, 2022 |
Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 Prospectus Supplement No. 1 Dated May 10, 2022 (To Prospectus Dated April 19, 2022) Kraig Biocraft Laboratories, Inc. 306,124,163 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the ?Prospectus Supplement?) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc., a Wyoming |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRAIG B |
|
| April 19, 2022 |
KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262631 Registration No. 333-255041 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 306,124,163 Shares of Class A Common Stock Pursuant to this prospectus, the selling shareholders identified herein (each a ?Selling Shareholder? and, collectively, the ?Selling Shareholders?) are offering on a resale basis, up to 306,124,163 shares of common stock, |
|
| April 14, 2022 |
As submitted to the Securities and Exchange Commission on April 14, 2022 As submitted to the Securities and Exchange Commission on April 14, 2022 Registration No. |
|
| April 14, 2022 |
EX-FILING FEES 3 ex107.htm Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 KRAIG BIOCRAFT LABORATORIES, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Proposed Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee(1) Equity Units consisting of shares of Class A Common Stock, no par value, and warrants to p |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 (January 20, 2022) KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or |
|
| April 7, 2022 |
Kraig Biocraft Laboratories, Inc. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 Tel. (734) 619-8066 VIA EDGAR Mr. Alan Campbell United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 April 7, 2022 Re: Kraig Biocraft Laboratories, Inc. Registration Statement on Form S-1 Filed February 10, 2022 File |
|
| March 23, 2022 |
As submitted to the Securities and Exchange Commission on March 23, 2022 As submitted to the Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| March 23, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 KRAIG BIOCRAFT LABORATORIES, INC. |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| March 16, 2022 |
Exhibit 4.2 Description of Securities General Our original articles of incorporation authorized 60,000,000 shares of Class A common stock, 25,000,000 shares of Class B common stock with no par value per share and 10,000,000 shares of preferred stock with no par value per share. On March 18, 2009, we amended our articles of incorporation to provide for unlimited authorized shares, no par value, of |
|
| March 16, 2022 |
EX-21.1 SUBSIDIARIES OF REGISTRANT Name State of Incorporation Prodigy Textiles Ltd (Vietnam) |
|
| February 10, 2022 |
As submitted to the Securities and Exchange Commission on February 10, 2022 As submitted to the Securities and Exchange Commission on February 10, 2022 Registration No. |
|
| February 10, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-1 KRAIG BIOCRAFT LABORATORIES, INC. |
|
| January 20, 2022 |
Form of Warrant dated January 18, 2022 (21) Exhibit 4.2 EXECUTION VERSION WARRANT A THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT |
|
| January 20, 2022 |
Form of Amended and Restated IP Security Agreement January 18, 2022 (21) Exhibit 10.4 EXECUTION VERSION AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this ?Agreement?), dated as of January 18, 2022, is made by Kraig Biocraft Laboratories, Inc., a Michigan Corporation (?Grantor?), in favor of YA II PN, LTD. (the ?Secured Party?), a Cayman Island exempted company. WITNESSETH: WHEREAS, pursuant to that certain |
|
| January 20, 2022 |
Form of Amended and Restated Guaranty Agreement January 18, 2022 (21) Exhibit 10.2 EXECUTION VERSION AMENDED AND RESTATED GLOBAL GUARANTY AGREEMENT This GLOBAL GUARANTY AGREEMENT (the ?Guaranty?) is made as of January 18, 2022, by and among PRODIGY TEXTILES (?PT?), a Vietnam LLC, ( PT is referred to as the ?Guarantor?), in favor of YAII PN, LTD. (the ?Investor?) with respect to all obligations of KRAIG BIOCRAFT LABORATORIES, INC. (the ?Company?), a Wyoming corporati |
|
| January 20, 2022 |
Form of Securities Purchase Agreement dated January 18, 2022 (21) Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of January 18, 2022, is between KRAIG BIOCRAFT LABORATORIES, INC., a company incorporated under the laws of the State of Wyoming, with principal executive offices located at 2723 South State Street ? Suite 150, Ann Arbor, MI 48104 (the ?Company?), and each of the investors l |
|
| January 20, 2022 |
Kraig Biocraft Laboratories Closes Additional Funding Agreement Exhibit 99.1 Kraig Biocraft Laboratories Closes Additional Funding Agreement Robust financial strength positions Company to deploy Impact Capital ANN ARBOR, Mich., ? January 20, 2022? Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (?Company? or ?Kraig Labs?), the biotechnology company focused on the development and commercialization of spider silk, announces the completion of an additional $3 mil |
|
| January 20, 2022 |
Form of Amended and Restated Security Agreement January 18, 2022 (21) Exhibit 10.3 EXECUTION VERSION AMENDED AND RESTATED SECURITY AGREEMENT THIS SECURITY AGREEMENT (the ?Agreement?) is entered into as of January 18, 2022, by and among KRAIG BIOCRAFT LABORATORIES, INC., (the ?Company?), a Wyoming corporation, PRODIGY TEXTILES (?Prodigy?), organized under the laws of Vietnam, (referred to as the ?Guarantor,? and together with the Company, the ?Grantors?) in favor of |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2022 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) |
|
| January 20, 2022 |
Form of Registration Rights Agreement January 18, 2022 (21) Exhibit 10.5 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of January 18, 2022 by and among KRAIG BIOCRAFT LABORATORIES, INC., INC., a Wyoming corporation (the ?Company?), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the ?Investor?). WHEREAS: A. In connection with the Securities Purchase Agreement by and among th |
|
| January 20, 2022 |
Form of Convertible Debenture dated January 18, 2022 (21) Exhibit 4.1 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC |
|
| December 3, 2021 |
As submitted to the Securities and Exchange Commission on December 3, 2021 As submitted to the Securities and Exchange Commission on December 3, 2021 Registration No. |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRA |
|
| August 25, 2021 |
As submitted to the Securities and Exchange Commission on August 25, 2021 As submitted to the Securities and Exchange Commission on August 25, 2021 Registration No. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRAIG BI |
|
| May 26, 2021 |
As submitted to the Securities and Exchange Commission on May 26, 2021 As submitted to the Securities and Exchange Commission on May 26, 2021 Registration No. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRA |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 (March 26, 2021) KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or ot |
|
| April 21, 2021 |
KRAIG BIOCRAFT LABORATORIES, INC. 207,750,197 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(1) Registration No. 333-255041 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 207,750,197 Shares of Class A Common Stock Pursuant to this prospectus, the selling shareholders identified herein (each a ?Selling Shareholder? and, collectively, the ?Selling Shareholders?) are offering on a resale basis, up to 207,750,197shares of common stock, no par value per share (the ? |
|
| April 20, 2021 |
Kraig Biocraft Laboratories, Inc. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 Tel. (734) 619-8066 VIA EDGAR Ms. Laura Crotty United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 April 20, 2021 Re: Kraig Biocraft Laboratories, Inc. Registration Statement on Form S-1 Filed April 5, 2021 File No. |
|
| April 15, 2021 |
As submitted to the Securities and Exchange Commission on April 15, 2021 Registration No. |
|
| April 14, 2021 |
As submitted to the Securities and Exchange Commission on April 14, 2021 Registration No. |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction |
|
| April 5, 2021 |
Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (6) As submitted to the Securities and Exchange Commission on April 5, 2021 Registration No. |
|
| March 26, 2021 |
Form of IP Security Agreement(8) Exhibit 10.4 INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this ?Agreement?), dated as of March 25, 2021, is made by Kraig Biocraft Laboratories, Inc., a Michigan Corporation (?Grantor?), in favor of YA II PN, LTD. (the ?Secured Party?), a Cayman Island exempted company. WITNESSETH: WHEREAS, pursuant to that certain Securities Purchase Agreement, dated of |
|
| March 26, 2021 |
Form of Registration Rights Agreement(8) Exhibit 10.5 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of March 25, 2021, by and among KRAIG BIOCRAFT LABORATORIES, INC., a Wyoming corporation (the ?Company?), and YA II PN, LTD., a Cayman Islands exempt company (the ?Investor?). WHEREAS: A. In connection with the Securities Purchase Agreement by and among the parties hereto of |
|
| March 26, 2021 |
Kraig Biocraft Laboratories Secures $4 Million Dollars of Expansion Capital Exhibit 99.1 Kraig Biocraft Laboratories Secures $4 Million Dollars of Expansion Capital ANN ARBOR, Mich., – March 26, 2021 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization a |
|
| March 26, 2021 |
Exhibit 10.2 GLOBAL GUARANTY AGREEMENT This GLOBAL GUARANTY AGREEMENT (the ?Guaranty?) is made as of March 25, 2021, by and among PRODIGY TEXTILES (?PT?), a Vietnam LLC, ( PT is referred to as the ?Guarantor?), in favor of YAII PN, LTD. (the ?Investor?) with respect to all obligations of KRAIG BIOCRAFT LABORATORIES, INC. (the ?Company?), a Wyoming corporation, owes to the Investor. Capitalized ter |
|
| March 26, 2021 |
Form of Securities Purchase Agreement(8) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of March 25, 2020, by and among KRAIG BIOCRAFT LABORATORIES, INC., a Wyoming corporation (the ?Company?), and YA II PN, LTD., a Cayman Islands exempt company (?Investor?). WITNESSETH WHEREAS, the Company and the Investor are executing and delivering this Agreement in reliance upon an exemptio |
|
| March 26, 2021 |
Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (the ?Agreement?) is entered into as of March 25, 2021, by and among KRAIG BIOCRAFT LABORATORIES, INC., (the ?Company?), a Wyoming corporation, PRODIGY TEXTILES (?Prodigy?), organized under the laws of Vietnam, (referred to as the ?Guarantor,? and together with the Company, the ?Grantors?) in favor of YA II PN, LTD. (the ?Secured Party?), a C |
|
| March 26, 2021 |
Exhibit 4.2 WARRANT THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED |
|
| March 26, 2021 |
Form of Convertible Debenture (8) Exhibit 4.1 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC |
|
| March 26, 2021 |
Form of A&R Convertible Debenture(8) Exhibit 4.3 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) (C |
|
| March 12, 2021 |
Exhibit 4.2 Description of Securities General Our original articles of incorporation authorized 60,000,000 shares of Class A common stock, 25,000,000 shares of Class B common stock with no par value per share and 10,000,000 shares of preferred stock with no par value per share on a pre-reverse split basis. On March 18, 2009, we amended our articles of incorporation to provide for unlimited authori |
|
| March 12, 2021 |
EX-21.1 SUBSIDIARIES OF REGISTRANT Name State of Incorporation Prodigy Textiles Ltd (Vietnam) |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of i |
|
| February 18, 2021 |
As submitted to the Securities and Exchange Commission on February 18, 2021 Registration No. |
|
| February 8, 2021 |
As submitted to the Securities and Exchange Commission on February 8, 2021 Registration No. |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement KRAIG BIOCRAFT LABORATORIES |
|
| February 2, 2021 |
KRAIG BIOCRAFT LABORATORIES, INC. 2723 South State Street, Suite 150 Ann Arbor, Michigan 48104 February 2, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Mail Stop 4631 Washington, DC 20549 Re: Kraig Biocraft Laboratories, Inc. Preliminary Information Statement on Schedule 14C Filed January 25, 2021 File No |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 000-56232 83-0458707 (State or other jurisdiction of incorporation) ( |
|
| January 26, 2021 |
Exhibit 99.1 Kraig Biocraft Laboratories and MtheMovement by Kings Group sign Exclusive Purchase and Sales Agreement for up to potentially $40 million Kraig Labs and Kings Group to jointly own SpydaSilk™ apparel brand, Joint Venture is the first large-scale Spider Silk Commercialization Agreement ANN ARBOR, Mich., – January 26, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “K |
|
| January 26, 2021 |
Exhibit 10.2 **CERTAIN INFORMATION, MARKED BY [******], HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.** Amendment to Strategic Partnership Agreement Dated November 23, 2020 The parties to the strategic partnership agreement dated November 23, 2020, Mthemovement Kings Pte Ltd and Kraig Biocraft Laboratories, Inc., for good and v |
|
| January 26, 2021 |
Strategic Partnership Agreement between the Company and Mthemovement Kings Pte Ltd. (17) Exhibit 10.1 **CERTAIN INFORMATION, MARKED BY [******], HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.** Strategic Partnership Agreement: This Strategic Partnership Agreement (SPA) dated November 23, 2020 is made between: Kraig Biocraft Laboratories, Inc. Of 2723 South State Street Suite 150Ann Arbor, Michigan 48104 (hereafter “ |
|
| January 25, 2021 |
January 25, 2021 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Kraig Biocraft Laboratories, Inc. Preliminary Schedule 14C Dear Sir or Madam: We are counsel to Kraig Biocraft Laboratories, Inc. (the ?Company?). Pursuant to Rule 14c-2 of the Securities Exchange Act of 1934, we are filing the enclosed Preliminary Information Statement on Schedule 14C on behalf of t |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement KRAIG BIOCRAFT LABORATORIES |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KRAIG BIOCRAFT LABORATORIES, INC. (Name of Company) Class A Common Stock (Title of Class of Securities) 50075W (CUSIP Number) Kim Thompson 2723 South State St., Suite 150, Ann Arbor, Michigan 48104 (734) 619-8066 (Name, Address and Telephone Number of Person Authorized to |
|
| December 11, 2020 |
Specimen Share Certificate (filed herewith) Exhibit 4.1 |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0458707 (State of incorporation or organization) (I.R.S. Employer Identification No.) 2723 South |
|
| December 11, 2020 |
Securities Purchase Agreement (19) EX-10.1 4 ex10-1.htm Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 11, 2020, by and among KRAIG BIOCRAFT LABORATORIES, INC., a Wyoming corporation (the “Company”), and YA II PN, LTD., a Cayman Islands exempt company (“Investor”). WITNESSETH WHEREAS, the Company and the Investor are executing and delivering t |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) |
|
| December 11, 2020 |
Kraig Biocraft Laboratories Secures Bridge Funding and Files to Become Fully Reporting Company EX-99.1 5 ex99-1.htm Exhibit 99.1 Kraig Biocraft Laboratories Secures Bridge Funding and Files to Become Fully Reporting Company ANN ARBOR, Mich., – December 11, 2020 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $950,000 in bridge financing and simultaneously filed with the SEC to become a mandatory, fully reporting company. Toda |
|
| December 11, 2020 |
Warrant issued December 11, 2020 (19) EX-4.2 3 ex4-2.htm Exhibit 4.2 EXECUTION VERSION WARRANT THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER T |
|
| December 11, 2020 |
EX-4.1 2 ex4-1.htm Exhibit 4.1 EXECUTION VERSION NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORD |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 |
|
| August 24, 2020 |
As submitted to the Securities and Exchange Commission on August 24, 2020 Registration No. |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRAI |
|
| June 2, 2020 |
Form Nominating and Governance Charter (16) Exhibit 99.3 CHARTER OF THE NOMINATING AND GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS OF KRAIG BIOCRAFT LABORATORIES, INC. (Adopted by the Board of Directors of Kraig Biocraft Laboratories, Inc. (the “Company”) on [ ], 2020; effective upon the effectiveness of the Company’s registration statement on Form S-1 relating to the uplisting of its common stock and certain warrants on the Nasdaq Capit |
|
| June 2, 2020 |
Form of Audit Committee Charter (16) Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KRAIG BIOCRAFT LABORATORIES, INC. (Adopted by the Board of Directors of Kraig Biocraft Laboratories, Inc. (the “Company”) on [ ], 2020; effective upon the effectiveness of the Company’s registration statement on Form S-1 relating to the uplisting of its common stock and certain warrants on the Nasdaq Capital Market) I. PURPOS |
|
| June 2, 2020 |
Exhibit 14.2 KRAIG BIOCRAFT LABORATORIES, INC. CODE OF BUSINESS CONDUCT AND ETHICS I. PURPOSE This Code of Business Conduct and Ethics (the “Code”) contains general guidelines for conducting the business of Kraig Biocraft Laboratories, Inc., a Wyoming company, and its subsidiaries and affiliates (collectively, the “Company”) consistent with the highest standards of business ethics, and is intended |
|
| June 2, 2020 |
As submitted to the Securities and Exchange Commission on June 2, 2020 Registration No. |
|
| June 2, 2020 |
Form of Compensation Charter (16) Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF KRAIG BIOCRAFT LABORATORIES, INC. (Adopted by the Board of Directors of Kraig Biocraft Laboratories, Inc. (the “Company”) on [ ], 2020; effective upon the effectiveness of the Company’s registration statement on Form S-1 relating to the uplisting of its common stock and certain warrants on the Nasdaq Capital Market) I. |
|
| April 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-146316 KRA |
|
| April 20, 2020 |
Exhibit 99.1 ANN ARBOR, Mich., – April 16, 2020 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk based fibers, announced, at a press conference held after today’s market close, that it successfully developed a new technology platform, based on a non-CRISPR gene editing knock-in knock-out technology. Other than the silkworm’s rem |
|
| April 20, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2020 (April 16, 2020) KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of |
|
| March 27, 2020 |
KBLB / Kraig Biocraft Laboratories, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-[ ] KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issu |
|
| March 27, 2020 |
2019 Employee Stock Option Plan (15) Exhibit 10.16 KRAIG BIOCRAFT LABORATORIES, INC. 2019 STOCK OPTION PLAN SECTION 1. PURPOSE The purposes of this Stock Option Plan (the “Plan”) are to encourage selected employees, officers, directors and consultants of Kraig Biocraft Laboratories, Inc. (together with any successor thereto, the “Company”) and its Affiliates (as defined below) to acquire a proprietary interest in the growth and perfo |
|
| March 27, 2020 |
EX-21.1 SUBSIDIARIES OF REGISTRANT Name State of Incorporation Prodigy Textiles Ltd (Vietnam) |
|
| March 20, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 ANN ARBOR, Mich., – March 19, 2020 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces that beginning today, it is furloughing all non-essential staff until at least April 1, 2020, due to concerns regarding the spread of COVID-19. The implementation of these furloughs is in line with the le |
|
| March 20, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) (C |
|
| March 17, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2020 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-146316 83-0458707 (State or other jurisdiction of incorporation) (C |
|
| March 17, 2020 |
Exhibit 99.1 ANN ARBOR, Mich., – March 17, 2020 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces the rescheduling of the upcoming press conference. The Company’s operations have not been directly affected by COVID-19. To ensure continued safe operations for our staff and facility, the Kraig Labs research center will not |
|
| February 27, 2020 |
Exhibit 99.1 Kraig Biocraft Laboratories Set to Unveil Major Scientific Breakthrough in Spider Silk Based Polymers ANN ARBOR, Mich., – February 27, 2020 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces that management will host an online presentation to introduce a game changing Spider Silk technological breakthrough. Th |
|
| February 27, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 333-164316 83-0458707 (State or other jurisdiction of incorporation) |
|
| November 13, 2019 |
KBLB / Kraig Biocraft Laboratories, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exa |
|
| August 12, 2019 |
KBLB / Kraig Biocraft Laboratories, Inc. 10-Q - Quarterly Report - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact Na |
|
| July 29, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0458707 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 15, 2019 |
Dear Kraig Labs Family, Last week we shared the news of the Company’s upcoming annual shareholder meeting to be held on July 24th. |
|
| July 15, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2019 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0458707 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2019 |
Kraig Biocraft Laboratories to host annual shareholder meeting Kraig Biocraft Laboratories to host annual shareholder meeting ANN ARBOR, Mich., – July 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company will be holding its 2019 annual shareholder meeting on Wednesday, July 24, at 10 a.m. EDT, at the East Lansing Marriott at University place, located at 300 M. |
|
| July 11, 2019 |
KRAIG BIOCRAFT LABORATORIES, INC. 2723 South State St. Suite 150 Ann Arbor, Michigan 48104 (734) 619-8066 TO THE SHAREHOLDERS OF KRAIG BIOCRAFT LABORATORIES, INC.: You are cordially invited to attend the 2019 annual shareholder meeting of Kraig Biocraft Laboratories, Inc. (the “Company” or “Kraig”) to be held at 10:00 a.m., eastern standard time, at East Lansing Marriott at University Place, 300 M |
|
| July 11, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2019 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0458707 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2019 |
KBLB / Kraig Biocraft Laboratories, Inc. 10-Q Quarterly Report PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact N |
|
| March 29, 2019 |
KBLB / Kraig Biocraft Laboratories, Inc. PRIMARY DOCUMENT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| March 11, 2019 |
Form of Purchase Agreement dated March 8, 2019 (7) SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated March 8, 2019 (the “Effective Date”), by and between Kraig Biocraft Laboratories, Inc. |
|
| March 11, 2019 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2019 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0458707 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 11, 2019 |
Form of Warrant issued pursuant to that certain Purchase Agreement dated as of March 8, 2019 (7) NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON AN EXEMPTION FROM THEREGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. |
|
| March 11, 2019 |
Kraig Biocraft Laboratories Closes Financing Deal Kraig Biocraft Laboratories Closes Financing Deal Kraig Labs secures funding to expand production of its recombinant spider silk ANN ARBOR, Mich. |
|
| November 13, 2018 |
KBLB / Kraig Biocraft Laboratories, Inc. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exa |
|
| August 10, 2018 |
KBLB / Kraig Biocraft Laboratories, Inc. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact Na |
|
| May 11, 2018 |
KBLB / Kraig Biocraft Laboratories, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact N |
|
| May 1, 2018 |
Kraig Biocraft Laboratories Granted Long Sought License for Business Operations in Vietnam; Prepares for Grand Opening Issuance of License seen as the most significant commercial event in the biotechnology Company’s development of spider silk based materials ANN ARBOR, Mich. |
|
| May 1, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2018 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0459707 (State or other jurisdiction of incorporation or organization) (I |
|
| March 23, 2018 |
KBLB / Kraig Biocraft Laboratories, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| November 15, 2017 |
KBLB / Kraig Biocraft Laboratories, Inc. PRIMARY DOCUMENT Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 SEC File Number 333-192272 CUSIP Number 04521X109 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 15, 2017 |
KBLB / Kraig Biocraft Laboratories, Inc. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exa |
|
| August 14, 2017 |
KBLB / Kraig Biocraft Laboratories, Inc. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact Na |
|
| June 12, 2017 |
KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 Shares of Class A Common Stock Prospectus Supplement No. 3 Dated June 12, 2017 (To Prospectus Dated June 2, 2015, As Amended by Prospectus Supplement No. 1 Dated October 20, 2016 and Prospectus Supplement No. 2 Dated December 7, 2016) KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 Shares of Class A Common Stock This Prospectus Supplement No. 3 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft |
|
| May 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC |
|
| May 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 9 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KRAIG BIOCRAFT LABORATORIES, INC. (Exact Name of Small Business Issuer in its Charter) Wyoming 2820 83-0459707 (State of Incorporation) (Primary Standard Classification Code) (IRS Employer ID No.) 2723 South State St., Suite 150, Ann Arbor, Mic |
|
| March 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| December 7, 2016 |
KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 Shares of Class A Common Stock Prospectus Supplement No. 2 Dated December 7, 2016 (To Prospectus Dated June 2, 2015, As Amended by Prospectus Supplement No. 1 Dated October 20, 2016) KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 Shares of Class A Common Stock This Prospectus Supplement No. 2 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc. (the “Company,” “we,” “us,” or “ |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exa |
|
| November 14, 2016 |
Exhibit 32.1 and 32.2 CERTIFICATION OF DISCLOSURE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Kraig Biocraft Laboratories, Inc. (the "Company") on Form 10-Q for the period ending June 30, 2016as filed with the Securities and Exchange Commission on the date hereof (the "Report") I, Kim Thompson, |
|
| October 21, 2016 |
KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 Shares of Class A Common Stock Prospectus Supplement No. 1 Dated October 20, 2016 (To Prospectus Dated June 2, 2015, As Amended by Preliminary Prospectus Amendment No. 8 Dated June 9, 2016) KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 Shares of Class A Common Stock This Prospectus Supplement No. 1 (the “Prospectus Supplement”) updates and supplements the prospectus of Kraig Biocraft Laboratories, Inc. (the “Company,” “we,” “us |
|
| August 12, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact Na |
|
| August 12, 2016 |
Exhibit 32.1 and 32.2 CERTIFICATION OF DISCLOSURE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Kraig Biocraft Laboratories, Inc. (the "Company") on Form 10-Q for the period ending June 30, 2016as filed with the Securities and Exchange Commission on the date hereof (the "Report") I, Kim Thompson, |
|
| August 12, 2016 |
Exhibit 32.1 and 32.2 CERTIFICATION OF DISCLOSURE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Kraig Biocraft Laboratories, Inc. (the "Company") on Form 10-Q for the period ending June 30, 2016as filed with the Securities and Exchange Commission on the date hereof (the "Report") I, Kim Thompson, |
|
| July 29, 2016 |
Blueprint PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-199820 KRAIG BIOCRAFT LABORATORIES, INC. 110,000,000 shares of Class A Common Stock This prospectus relates to the resale of up to 110,000,000 shares of the common stock of Kraig Biocraft Laboratories, Inc., a Wyoming corporation, which shares will be offered and sold by the selling shareholder, Calm Seas Capital, LLC, a Ne |
|
| June 16, 2016 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 8 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KRAIG BIOCRAFT LABORATORIES, INC. (Exact Name of Small Business Issuer in its Charter) Wyoming 2820 83-0459707 (State of Incorporation) (Primary Standard Classification Code) (IRS Employer ID No.) 2723 South State St., Suite 150, Ann |
|
| June 9, 2016 |
Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc. June 9, 2016 Office of the Secretary U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Kraig Biocraft Laboratories, Inc. Post-Effective Amendment to Form S-1 Filed May 27, 2016 File No. 333-199820 Dear Mr. Ingram, This letter is provided in response to your letter dated June 8, 2016 (the “Comment Letter”) regarding the above-refer |
|
| June 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 8 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KRAIG BIOCRAFT LABORATORIES, INC. (Exact Name of Small Business Issuer in its Charter) Wyoming 2820 83-0459707 (State of Incorporation) (Primary Standard Classification Code) (IRS Employer ID No.) 2723 South State St., Suite 150, Ann Arbor, Mic |
|
| May 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 7 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KRAIG BIOCRAFT LABORATORIES, INC. (Exact Name of Small Business Issuer in its Charter) Wyoming 2820 83-0459707 (State of Incorporation) (Primary Standard Classification Code) (IRS Employer ID No.) 2723 South State St., Suite 150, Ann Arbor, Mic |
|
| May 16, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 16, 2016 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0459707 (State or other jurisdiction of incorporation or organ |
|
| May 16, 2016 |
EX-99 2 ex991.htm ADDITIONAL EXHIBITS Spider Sense Q1 2016 Letter from CEO & COO Like a germinating seed, our Company has one choice. That choice is growth. We are writing to keep you informed of the work that has been going on behind the scenes and to provide some perspective on the Company’s plans for 2016. This is also an opportunity to describe some of the inevitable business obstacles, presen |
|
| May 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact N |
|
| May 10, 2016 |
Kraig Biocraft Laboratories Announces Creation of Four New Transgenics Blueprint Kraig Biocraft Laboratories Announces Creation of Four New Transgenics Kraig Labs continues to expand its inventory of revolutionary transgenics ANN ARBOR, Mich. |
|
| May 10, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2016 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0459707 (State or other jurisdiction of incorporation or organ |
|
| March 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| December 7, 2015 |
kblbex991.htm Exhibit 99.1 Kraig Biocraft Laboratories Announces Highlights of Conference Call Spider Silk poised for Commercialization ANN ARBOR, Mich., ? December 7, 2015 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (?Company?), the leading developer of advanced spider silk based fibers, announced highlights from its call with Shareholders and that a recording of the call is available at ww |
|
| December 7, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events kblb8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2015 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0459707 (State or other jurisdiction of incorporation or |
|
| November 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 kblb10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR o TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KR |
|
| August 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR o TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exact Na |
|
| June 9, 2015 |
Kraig Biocraft Laboratories Issues Letter to Shareholders kblbex991.htm Exhibit 99.1 Kraig Biocraft Laboratories Issues Letter to Shareholders LANSING, Mich., - June 9, 2015 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (?Company?), the leading developer of advanced spider silk based fibers, has provided a business update to shareholders via e-mail. The content of the e-mail message is as follows: Dear Shareholders, As the past several months have be |
|
| June 9, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events kblb8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2015 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0459707 (State or other jurisdiction of incorporation or orga |
|
| June 5, 2015 |
Kraig Biocraft Laboratories ESP kblbcorresp.htm Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805, Lansing, Michigan 48933 June 5, 2015 VIA EDGAR Pamela Long Assistant Director U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Kraig Biocraft Laboratories, Inc. Amendment No. 6 to Registration Statement on Form S-1 Filed June 2, 2015 File No. 3 |
|
| June 2, 2015 |
Kraig Biocraft Laboratories AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT kblbs1a.htm As filed with the Securities and Exchange Commission on June 2, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KRAIG BIOCRAFT LABORATORIES, INC. (Exact Name of Small Business Issuer in its Charter) Wyoming 2820 83-0459707 (State of Incorporation) (Primary Standard Classific |
|
| June 2, 2015 |
Kraig Biocraft Laboratories ESP kblbcorresp.htm Rachael Schmierer (Admitted NY & NJ) Email [email protected] June 2, 2015 US Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, DC 20549 Attn: Pamela Long, Assistant Director RE: Kraig Biocraft Laboratories, Inc. Amendment No. 5 to Registration Statement on Form S-1 Filed May 15, 2015 File No. 333-199820 Dear Ms. Long: On beh |
|
| May 15, 2015 |
Kraig Biocraft Laboratories ESP kblbcorresp.htm HUNTER TAUBMANFischer LLP New York ? Washington, DC ? Miami VIA EDGAR May 15, 2015 US Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, DC 20549 Attn: Pamela Long, Assistant Director RE: Kraig Biocraft Laboratories, Inc. Amendment No. 4 to Registration Statement on Form S-1 Filed April 3, 2015 File No. 333-199820 Dear Ms. Long: On b |
|
| May 15, 2015 |
As filed with the Securities and Exchange Commission on May 15, 2015 As filed with the Securities and Exchange Commission on May 15, 2015 Registration Statement No. |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to KRAIG BIOCRAFT LABORATORIES, INC. (Exa |
|
| April 30, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events kblb8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2015 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of registrant as specified in its charter) Wyoming 83-0459707 (State or other jurisdiction of incorporation or or |
|
| April 30, 2015 |
KRAIG BIOCRAFT LABORATORIES APPOINTS Hunter Taubman Weiss LLP AS SECURITIES COUNSEL kblbex991.htm Exhibit 99.1 KRAIG BIOCRAFT LABORATORIES APPOINTS Hunter Taubman Weiss LLP AS SECURITIES COUNSEL LANSING, Mich., –April 30th, 2015 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that it has retained the New York law firm of Hunter Taubman Weiss LLP as legal counsel for all securities related m |
|
| April 3, 2015 |
Kraig Biocraft Laboratories ESP kblbcorresp.htm Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805, Lansing, Michigan 48933 April 3, 2015 VIA EDGAR AND FEDEX Ms. Pamela Long, Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kraig Biocraft Laboratories, Inc. Amendment No. 3 to Registration Statement on Form S-1 Fil |
|
| April 3, 2015 |
As filed with the Securities and Exchange Commission on April 3, 2015 As filed with the Securities and Exchange Commission on April 3, 2015 Registration Statement No. |
|
| March 31, 2015 |
Warrant issued Mr. Jonathan R. Rice (18) Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED FOR RESALE UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES AND SUCH DISPOSITION FILED UNDER THE ACT, OR AN EXE |
|
| March 31, 2015 |
Exhibit 10.15 INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT between Kraig Biocraft Laboratories, Inc. (SPONSOR) and The University of Notre Dame du Lac (NOTRE DAME) 1. Scope of Work SPONSOR grants to NOTRE DAME and NOTRE DAME accepts support for basic research investigations under the direction of Dr. Malcolm Fraser at College of Science in the department of Biological Science as describe |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| March 9, 2015 |
As filed with the Securities and Exchange Commission on March 9, 2015 As filed with the Securities and Exchange Commission on March 9, 2015 Registration Statement No. |
|
| March 9, 2015 |
Kraig Biocraft Laboratories ESP kblbcorresp.htm Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805, Lansing, Michigan 48933 March 9, 2015 VIA EDGAR AND FEDEX Ms. Pamela Long, Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kraig Biocraft Laboratories, Inc. Amendment No. 2 to Registration Statement on Form S-1 Fil |
|
| January 30, 2015 |
KBLB / Kraig Biocraft Laboratories, Inc. S-1/A - - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on January 30 , 2015 Registration Statement No. |
|
| January 30, 2015 |
Exhibit 10.13 1 2 3 4 5 6 |
|
| January 30, 2015 |
Exhibit 10.11 License Agreement Between The University of Notre Dame du Lac and Kraig Biocraft Laboratories, Inc. This Agreement is made and entered into as of this 28th day of October, 2011 (“Effective Date”) between the University of Notre Dame du Lac, a corporation organized under the laws of the State of Indiana, (hereinafter NOTRE DAME), and Kraig Biocraft Laboratories, Inc., a for-profit cor |
|
| January 30, 2015 |
KBLB / Kraig Biocraft Laboratories, Inc. CORRESP - - Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805, Lansing, Michigan 48933 January 30, 2015 VIA EDGAR AND FEDEX Ms. Pamela Long, Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kraig Biocraft Laboratories, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed January 7, |
|
| January 30, 2015 |
Exhibit 10.12 INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT between Kraig Biocraft Laboratories, Inc. (SPONSOR) and The University of Notre Dame du Lac (NOTRE DAME) 1. Scope of Work SPONSOR grants to NOTRE DAME and NOTRE DAME accepts support for basic research investigations under the direction of Dr. Malcolm Fraser at College of Science in the department of Biological Science as describe |
|
| January 21, 2015 |
KRAIG BIOCRAFT LABORATORIES ANNOUNCES NEW CHIEF OPERATIONS OFFICER Exhibit 99.1 KRAIG BIOCRAFT LABORATORIES ANNOUNCES NEW CHIEF OPERATIONS OFFICER Kraig Labs strengthens management team, appointing new Chief Operations Officer with strong product development and commercialization experience LANSING, Mich., –January 21, 2015 - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces Jon Rice |
|
| January 21, 2015 |
Employment Agreement, dated January 19, 2015, between the Company and Mr. Jonathan R. Rice (11) Exhibit 10.1 At-Will Employment In consideration of the mutual covenants set forth below, and for other valuable consideration, the sufficiency and adequacy of which is hereby acknowledged, Kraig Biocraft Laboratories, Inc., (hereafter Employer or Company or Kraig) agrees to hire Jon Rice, (hereafter Mr. Rice or Employee) on an at-will basis and Employee agrees to work for Employer as set forth in |
|
| January 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2015 Kraig Biocraft Laboratories, Inc. - (Exact name of Registrant as specified in charter) Wyoming 333-146316 83-0459707 (State of Incorporation) (Commission File No.) |
|
| January 7, 2015 |
KBLB / Kraig Biocraft Laboratories, Inc. S-1/A - - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on January 7, 2015 Registration Statement No. |
|
| January 7, 2015 |
KBLB / Kraig Biocraft Laboratories, Inc. CORRESP - - Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805, Lansing, Michigan 48933 January 7, 2015 VIA EDGAR AND FEDEX Ms. Pamela Long, Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Kraig Biocraft Laboratories, Inc. Registration Statement on Form S-1 Filed November 3, 2014 File No. 333- |
|
| January 7, 2015 |
CALM SEAS CAPITAL, LLC 4650 Wedekind Rd. Suite 2 Sparks, NV 89431 Exhibit 10.10 CALM SEAS CAPITAL, LLC 4650 Wedekind Rd. Suite 2 Sparks, NV 89431 October 2nd, 2014 Kim Thompson, CEO Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805 Lansing, MI 48933 In Re: Proposed Equity Line Transaction - Term Sheet Dear Mr. Thompson: This Letter is to serve as a binding Memorandum of Understanding for an Equity Line transaction by Calm Seas Capital, LLC (“ |
|
| November 3, 2014 |
KBLB / Kraig Biocraft Laboratories, Inc. S-1 - Registration Statement - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on November 3, 2014 Registration Statement No. |
|
| October 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 kblb10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com |
|
| October 3, 2014 |
CALM SEAS CAPITAL, LLC 4650 Wedekind Rd. Suite 2 Sparks, NV 89431 October 2nd, 2014 Kim Thompson, CEO Kraig Biocraft Laboratories, Inc. 120 N. Washington Square, Suite 805 Lansing, MI 48933 In Re: Proposed Equity Line Transaction - Term Sheet Dear Mr. Thompson: This Letter is to serve as a binding Memorandum of Understanding for an Equity Line transaction by Calm Seas Capital, LLC (“Investor”) and |
|
| October 3, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2014 Kraig Biocraft Laboratories, Inc. - (Exact name of Registrant as specified in charter) Wyoming 333-146316 83-0459707 (State of Incorporation) (Commission File No.) ( |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 333-146316 KRAIG BIOC |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 kblb10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| May 13, 2014 |
Filed Pursuant to Rule 424(B)(3) File No. 333-189343 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 73,853,414 shares of Class A Common Stock This prospectus relates to the resale of up to 73,853,414 shares of the common stock of Kraig Biocraft Laboratories, Inc., a Wyoming corporation, which shares will be offered and sold by the selling shareholder, Calm Seas Capital, LLC, a Nevada limited liabili |
|
| April 30, 2014 |
- POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on April 30, 2014 Registration Statement No. |
|
| April 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of issue |
|
| April 1, 2014 |
- LATE FILING OF ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): xForm 10-K o Form 20-F o Form 11-K oForm 10-Q oForm 10-D oForm N-SAR For Period Ended: December 31, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For |
|
| January 27, 2014 |
KRAIG BIOCRAFT LABORATORIES, INC. 73,853,414 shares of Class A Common Stock Filed Pursuant to Rule 424(B)(3) and 424(c) File No. 333-189343 PROSPECTUS SUPPLEMENT NO. 1 KRAIG BIOCRAFT LABORATORIES, INC. 73,853,414 shares of Class A Common Stock This prospectus supplement amends the prospectus dated June 25, 2013 that relates to the resale of up to 73,853,414 shares of the common stock of Kraig Biocraft Laboratories, Inc., a Wyoming corporation, which shares will be offered |
|
| December 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q /A 10-Q/A 1 kblb10qa.htm QUARTERLY REPORT AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q /A (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period |
|
| December 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A 10-Q/A 1 kblb10qa.htm AMENDMENT TO QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri |
|
| December 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K /A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 333-146316 KRAIG BIOCRAFT LABORATORIES, INC. (Exact name of is |
|
| December 19, 2013 |
Articles of Amendment, filed with the Wyoming Secretary of State on December 17, 2013 (7) Exhibit 3.1 1 2 3 4 |
|
| December 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2013 Kraig Biocraft Laboratories, Inc. (Exact name of Registrant as specified in charter) Wyoming 333-146316 83-0459707 (State of Incorporation) (Commission File No.) ( |
|
| November 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2013 Kraig Biocraft Laboratories, Inc. (Exact name of Registrant as specified in charter) Wyoming 333-146316 83-0459707 (State of Incorporation) (Commission File No.) ( |
|
| November 22, 2013 |
Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (6) Exhibit 3.1 1 2 3 |
|
| November 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 kblb10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report |
|
| November 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2013 Kraig Biocraft Laboratories, Inc. (Exact name of Registrant as specified in charter) Wyoming 333-146316 83-0459707 (State of Incorporation) (Commission File No.) (I |
|
| October 30, 2013 |
Exhibit 16.1 |
|
| October 30, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2013 Kraig Biocraft Laboratories, Inc. (Exact name of Registrant as specified in charter) Wyoming 333-146316 83-0459707 (State of Incorporation) (Commission File No.) (I |
|
| August 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 kblb10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| August 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 1 |
|
| June 26, 2013 |
KRAIG BIOCRAFT LABORATORIES, INC. 73,853,414 shares of Class A Common Stock Filed Pursuant to Rule 424(B)(3) File No. 333-189343 PROSPECTUS KRAIG BIOCRAFT LABORATORIES, INC. 73,853,414 shares of Class A Common Stock This prospectus relates to the resale of up to 73,853,414 shares of the common stock of Kraig Biocraft Laboratories, Inc., a Wyoming corporation, which shares will be offered and sold by the selling shareholder, Calm Seas Capital, LLC, a Nevada limited liabili |
|
| June 14, 2013 |
Registration Statement - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on June 14, 2013 Registration Statement No. |
